Horizon Pharma PLC (HZNP) Given a $18.00 Price Target by Piper Jaffray Companies Analysts

Horizon Pharma PLC (NASDAQ:HZNP) has been assigned a $18.00 target price by equities research analysts at Piper Jaffray Companies in a report issued on Sunday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target points to a potential upside of 32.35% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. BidaskClub upgraded shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. UBS AG set a $16.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald set a $13.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a research note on Friday, July 28th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $14.00 price target on shares of Horizon Pharma PLC in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $18.00.

Shares of Horizon Pharma PLC (HZNP) opened at 13.59 on Friday. The stock’s market cap is $2.22 billion. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The company’s 50-day moving average is $13.09 and its 200-day moving average is $12.69.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. During the same quarter in the previous year, the firm earned $0.56 earnings per share. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. Equities analysts anticipate that Horizon Pharma PLC will post $1.07 EPS for the current year.

WARNING: “Horizon Pharma PLC (HZNP) Given a $18.00 Price Target by Piper Jaffray Companies Analysts” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/17/horizon-pharma-plc-hznp-given-a-18-00-price-target-by-piper-jaffray-companies-analysts-2.html.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Horizon Pharma PLC by 1.8% during the 2nd quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock worth $160,247,000 after buying an additional 239,014 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Horizon Pharma PLC by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock worth $154,105,000 after buying an additional 233,443 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Horizon Pharma PLC by 119.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after buying an additional 3,409,411 shares during the last quarter. Paulson & CO. Inc. purchased a new stake in shares of Horizon Pharma PLC during the 2nd quarter worth approximately $58,584,000. Finally, State Street Corp lifted its position in shares of Horizon Pharma PLC by 12.0% during the 2nd quarter. State Street Corp now owns 4,906,307 sh

Other research analysts also recently issued research reports about the stock. BidaskClub upgraded shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. UBS AG set a $16.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald set a $13.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a research note on Friday, July 28th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $14.00 price target on shares of Horizon Pharma PLC in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $18.00.

Shares of Horizon Pharma PLC (HZNP) opened at 13.59 on Friday. The stock’s market cap is $2.22 billion. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The company’s 50-day moving average is $13.09 and its 200-day moving average is $12.69.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. During the same quarter in the previous year, the firm earned $0.56 earnings per share. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. Equities analysts anticipate that Horizon Pharma PLC will post $1.07 EPS for the current year.

WARNING: “Horizon Pharma PLC (HZNP) Given a $18.00 Price Target by Piper Jaffray Companies Analysts” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/17/horizon-pharma-plc-hznp-given-a-18-00-price-target-by-piper-jaffray-companies-analysts-2.html.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Horizon Pharma PLC by 1.8% during the 2nd quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock worth $160,247,000 after buying an additional 239,014 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Horizon Pharma PLC by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock worth $154,105,000 after buying an additional 233,443 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Horizon Pharma PLC by 119.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after buying an additional 3,409,411 shares during the last quarter. Paulson & CO. Inc. purchased a new stake in shares of Horizon Pharma PLC during the 2nd quarter worth approximately $58,584,000. Finally, State Street Corp lifted its position in shares of Horizon Pharma PLC by 12.0% during the 2nd quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock worth $58,241,000 after buying an additional 524,187 shares during the last quarter. Institutional investors and hedge funds own 82.32% of the company’s stock.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply